Control method for quality and safety of colloidal bismuth pectin pharmaceutical composition

A quality control method, the technology of colloidal bismuth pectin, applied in the field of preparation and quality control of colloidal bismuth pectin dry suspension, can solve the problem that the curative effect of colloidal bismuth pectin cannot be further improved, and the control range of intrinsic viscosity is not specified. , Intrinsic viscosity standards are not specified, etc., to achieve the effect of eradicating Helicobacter pylori, scientific, reasonable and controllable quality standards, and improving safety

Active Publication Date: 2016-04-20
HUNAN WARRANT PHARM TECH DEV CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, the main reference standard for colloidal bismuth pectin raw materials is the second part of the "Chinese Pharmacopoeia" 2010 edition on colloidal bismuth pectin, but it does not specify the control range of its intrinsic viscosity
[0007] In addition, the standard number is WS1-(X-104)-96Z colloidal bismuth pectin new drug conversion standard stipulates the drug standard of the raw material colloidal bismuth pectin, but does not specify the standard of intrinsic viscosity in the colloidal bismuth pectin raw material drug , and for different colloidal bismuth pectin pharmaceutical compositions, the dosage forms are different, the intrinsic viscosity standards are different, and the curative effects are also different
[0008] The Chinese patent with application number 201110300984.1 proposes a quality detection method for colloidal bismuth pectin pharmaceutical composition. In view of the current quality control method for colloidal bismuth pectin and its pharmaceutical preparations, the quality control of indicators related to curative effect is not rigorous enough, so that The problem of poor controllability of products with poor curative effect
The measurement items and indicators of intrinsic viscosity, uniformity, and galacturonic acid content have been added to effectively ensure the clinical efficacy of the product, but no more detailed research has been done on each technical parameter, so that those skilled in the art cannot go further Improve the curative effect of colloidal bismuth pectin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Control method for quality and safety of colloidal bismuth pectin pharmaceutical composition
  • Control method for quality and safety of colloidal bismuth pectin pharmaceutical composition
  • Control method for quality and safety of colloidal bismuth pectin pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0050] 1. Preparation of colloidal pectin bismuth

[0051] (1) Add 166.67g purified water to the reaction flask, add 29.22g of bismuth nitrate; add about 23.78g of 40% potassium hydroxide solution, adjust the pH to 6-8, and make the hydrolysis complete (that is, the retest pH is constant) Then, filter to obtain the filter cake bismuth hydroxide; then put 40.56g of purified water and 17.89g of sorbitol into the beaker. After the sorbitol is dissolved, add the filter cake bismuth hydroxide, stir and add 40% potassium hydroxide About 50g of the solution, stir to make it fully dissolved, and get the bismuth salt solution for later use;

[0052] (2) Add the bismuth salt solution prepared in step (1) to the reaction flask, stir, add 49ml purified water, add pectin soft material at room temperature, after the addition, heat up to about 40 ℃ and stir, keep warm and react for 0.5 hours, then add 105g of purified water, temperature controlled at 30-35°C and stirred for 1.5 hours; after the ...

Embodiment 2

[0054] Example 2. Preparation of colloidal bismuth pectin dry suspension

[0055] Prescription: colloidal pectin bismuth 1000 (based on 150g bismuth)

[0056] Mannitol 455g

[0057] Disodium hydrogen phosphate 15g

[0058] Production method: 1) Weigh the ingredients in the prescription on an electronic scale according to the ratio in the prescription; 2) Put the weighed colloidal bismuth pectin, disodium hydrogen phosphate and mannitol into the total mixer in turn Mix, the mixing time is 30 minutes, the speed of the total mixer is 50Hz; 3) After mixing, sample the product (sampling volume is about 30g) for testing. After passing the test, divide it into 1000 bags, vacuum seal, label, store, Packaging and storage.

Embodiment 3

[0059] Example 3. Preparation of colloidal bismuth pectin dry suspension

[0060] Prescription: Colloidal pectin bismuth 900kg

[0061] Mannitol 409.5kg

[0062] Disodium hydrogen phosphate 13.5kg

[0063] Specification: 150mg (calculated as bismuth)

[0064] Production method: 1) Weigh the ingredients in the prescription on an electronic scale according to the ratio in the prescription; 2) Put the weighed colloidal bismuth pectin, disodium hydrogen phosphate and mannitol into the total mixer in turn Mix, the mixing time is 30 minutes, and the speed of the total mixer is 50Hz; 3) After mixing, sample the product (sampling volume is about 30g) for testing. After passing the test, divide it into 900,000 bags, vacuum seal, label, and store ,Packaging and storage.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a control method for quality and safety of a colloidal bismuth pectin pharmaceutical composition. The pharmaceutical composition is in a dry suspension dosage form and is prepared from, by weight, 130-160 parts of colloidal bismuth pectin (according to bismuth) serving as the bulk pharmaceutical chemical, 420-460 parts of mannitol serving as filler and 10-20 parts of disodium hydrogen phosphate serving as flocculant and / or corrigent. The pharmaceutical composition is characterized in that the intrinsic viscosity of the pharmaceutical composition is controlled, the pharmaceutical stability and the treatment effect of the colloidal bismuth pectin dry suspension are improved, a significant impact will be imposed on improving technical progress of the product and the pharmaceutical industry, and the pharmaceutical composition will achieve obvious technical progress and promotion effects in the quality control field of the colloidal bismuth pectin.

Description

Technical field [0001] This application relates to the preparation of a colloidal bismuth pectin dry suspension and its quality control method. Specifically, this application also relates to a method for controlling the safety of a colloidal bismuth pectin pharmaceutical composition. Background technique [0002] Colloidal bismuth pectin is a compound of indeterminate composition formed by pectin and bismuth. As a raw material, it belongs to the gastric mucosal protective drug. It is characterized in that its molecule is composed of D-galacturonic acid methyl ester and D-galacturonaldehyde. The high molecular compound formed by the structural fragments of bismuth acid and potassium D-galacturonic acid and the new bismuth salt compound formed by the biological macromolecular acid radical. [0003] Colloidal bismuth pectin can form a stable colloidal dispersion in water and form a gel in artificial gastric juice. It has strong colloidal properties and has a strong affinity with the s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K31/732A61P1/04A61P31/04G01N11/06G01N21/78
CPCA61K9/145A61K33/245G01N11/06G01N21/78
Inventor 肖利辉周志刚刘海艳覃琳肖爱平
Owner HUNAN WARRANT PHARM TECH DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products